 | Up a level |
Number of items: 1.
McEwan, Phil, Morgan, Angharad R, Boyce, Rebecca, Bergenheim, Klas, Gause-Nilsson, Ingrid AM, Bhatt, Deepak L, Leiter, Lawrence A, Johansson, Peter A, Mosenzon, Ofri, Cahn, Avivit et al (show 1 more authors)
(2021)
The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial.
DIABETES OBESITY & METABOLISM, 23 (4).
pp. 1020-1029.
